Inhibition of granulocyte colony stimulating factor in the treatment of cancer
US-2016368980-A1 · Dec 22, 2016 · US
Anti-CTLA-4 antibody compositions
US9487581B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9487581-B2 |
| Application number | US-81789406-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 2, 2006 |
| Priority date | Mar 8, 2005 |
| Publication date | Nov 8, 2016 |
| Grant date | Nov 8, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising: a chelating agent at a concentration of about 0.01 mM to about 5.0 mM; histidine at a concentration of about 1 mM to about 100 mM; a surfactant at a concentration of about 0.01 mg/ml to about 10 mg/ml; trehalose at a concentration of about 100 mM to about 300 mM; and an antibody at a concentration of about 1 mg/ml to about 200 mg/ml, wherein said antibody binds to human CTLA-4 and comprises the heavy chain CDR1, CDR2, and CD…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9487581B2 cover?
- The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.
- Who is the assignee on this patent?
- Abate Justin, Muthurania Kevin, Nema Sandeep, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/243. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).